HAEMONETICS CORP/MASS (HAE)
US4050241003 - Common Stock
Taking everything into account, HAE scores 6 out of 10 in our fundamental rating. HAE was compared to 187 industry peers in the Health Care Equipment & Supplies industry. HAE has an excellent profitability rating, but there are some minor concerns on its financial health. HAE has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
HAE had positive earnings in the past year.
In the past year HAE had a positive cash flow from operations.
Each year in the past 5 years HAE has been profitable.
HAE had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 4.90%, HAE belongs to the best of the industry, outperforming 83.42% of the companies in the same industry.
HAE has a better Return On Equity (14.09%) than 88.24% of its industry peers.
HAE has a Return On Invested Capital of 7.59%. This is amongst the best in the industry. HAE outperforms 86.63% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HAE is in line with the industry average of 8.19%.
The 3 year average ROIC (7.51%) for HAE is below the current ROIC(7.59%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.9% | ||
| ROE | 14.09% | ||
| ROIC | 7.59% |
ROA(3y)4.55%
ROA(5y)4.81%
ROE(3y)10.72%
ROE(5y)11.21%
ROIC(3y)7.51%
ROIC(5y)8.04%
1.3 Margins
With an excellent Profit Margin value of 9.10%, HAE belongs to the best of the industry, outperforming 83.42% of the companies in the same industry.
HAE's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 15.80%, HAE belongs to the best of the industry, outperforming 86.10% of the companies in the same industry.
HAE's Operating Margin has improved in the last couple of years.
HAE has a Gross Margin (54.02%) which is in line with its industry peers.
HAE's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.8% | ||
| PM (TTM) | 9.1% | ||
| GM | 54.02% |
OM growth 3Y24.43%
OM growth 5Y5.91%
PM growth 3Y-0.56%
PM growth 5Y9.58%
GM growth 3Y4.96%
GM growth 5Y3.61%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HAE is destroying value.
The number of shares outstanding for HAE has been increased compared to 1 year ago.
Compared to 5 years ago, HAE has less shares outstanding
HAE has a better debt/assets ratio than last year.
2.2 Solvency
HAE has an Altman-Z score of 2.73. This is not the best score and indicates that HAE is in the grey zone with still only limited risk for bankruptcy at the moment.
HAE's Altman-Z score of 2.73 is fine compared to the rest of the industry. HAE outperforms 65.78% of its industry peers.
The Debt to FCF ratio of HAE is 39.37, which is on the high side as it means it would take HAE, 39.37 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 39.37, HAE is in the better half of the industry, outperforming 67.91% of the companies in the same industry.
HAE has a Debt/Equity ratio of 1.39. This is a high value indicating a heavy dependency on external financing.
HAE has a Debt to Equity ratio of 1.39. This is amonst the worse of the industry: HAE underperforms 81.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.39 | ||
| Debt/FCF | 39.37 | ||
| Altman-Z | 2.73 |
ROIC/WACC0.89
WACC8.49%
2.3 Liquidity
A Current Ratio of 3.49 indicates that HAE has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.49, HAE is doing good in the industry, outperforming 62.57% of the companies in the same industry.
A Quick Ratio of 2.09 indicates that HAE has no problem at all paying its short term obligations.
HAE has a Quick ratio (2.09) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.49 | ||
| Quick Ratio | 2.09 |
3. Growth
3.1 Past
HAE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.48%, which is quite good.
The Earnings Per Share has been growing by 10.74% on average over the past years. This is quite good.
The Revenue has grown by 9.85% in the past year. This is quite good.
HAE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.23% yearly.
EPS 1Y (TTM)11.48%
EPS 3Y19.2%
EPS 5Y10.74%
EPS Q2Q%13.13%
Revenue 1Y (TTM)9.85%
Revenue growth 3Y14.57%
Revenue growth 5Y6.23%
Sales Q2Q%8.59%
3.2 Future
HAE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.65% yearly.
Based on estimates for the next years, HAE will show a quite strong growth in Revenue. The Revenue will grow by 8.79% on average per year.
EPS Next Y16.5%
EPS Next 2Y15.78%
EPS Next 3Y15.56%
EPS Next 5Y17.65%
Revenue Next Year7.65%
Revenue Next 2Y5.51%
Revenue Next 3Y6.63%
Revenue Next 5Y8.79%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 18.49, HAE is valued on the expensive side.
HAE's Price/Earnings ratio is rather cheap when compared to the industry. HAE is cheaper than 88.24% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.73. HAE is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 14.14, which indicates a correct valuation of HAE.
Based on the Price/Forward Earnings ratio, HAE is valued cheaply inside the industry as 89.84% of the companies are valued more expensively.
HAE is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.83, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.49 | ||
| Fwd PE | 14.14 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HAE indicates a rather cheap valuation: HAE is cheaper than 85.56% of the companies listed in the same industry.
HAE's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. HAE is cheaper than 68.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 121.77 | ||
| EV/EBITDA | 14.52 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
HAE has an outstanding profitability rating, which may justify a higher PE ratio.
HAE's earnings are expected to grow with 15.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.12
PEG (5Y)1.72
EPS Next 2Y15.78%
EPS Next 3Y15.56%
5. Dividend
5.1 Amount
HAE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HAEMONETICS CORP/MASS
NYSE:HAE (12/20/2024, 8:16:07 PM)
After market: 75.44 0 (0%)75.44
-1.46 (-1.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.5%
Inst Owner Change0.47%
Ins Owners0.9%
Ins Owner Change-1.92%
Market Cap3.79B
Analysts81.43
Price Target113.02 (49.81%)
Short Float %9.18%
Short Ratio7.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.9%
Min EPS beat(2)0.44%
Max EPS beat(2)3.35%
EPS beat(4)3
Avg EPS beat(4)3.29%
Min EPS beat(4)-0.02%
Max EPS beat(4)9.38%
EPS beat(8)7
Avg EPS beat(8)9.85%
EPS beat(12)11
Avg EPS beat(12)11.14%
EPS beat(16)13
Avg EPS beat(16)8.25%
Revenue beat(2)0
Avg Revenue beat(2)-0.46%
Min Revenue beat(2)-0.76%
Max Revenue beat(2)-0.16%
Revenue beat(4)2
Avg Revenue beat(4)1.58%
Min Revenue beat(4)-0.76%
Max Revenue beat(4)3.94%
Revenue beat(8)6
Avg Revenue beat(8)2.11%
Revenue beat(12)9
Avg Revenue beat(12)2.42%
Revenue beat(16)11
Avg Revenue beat(16)2.29%
PT rev (1m)0.91%
PT rev (3m)-1.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.59%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-0.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.37%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)-0.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.49 | ||
| Fwd PE | 14.14 | ||
| P/S | 2.78 | ||
| P/FCF | 121.77 | ||
| P/OCF | 44.6 | ||
| P/B | 4.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.52 |
EPS(TTM)4.08
EY5.41%
EPS(NY)5.34
Fwd EY7.07%
FCF(TTM)0.62
FCFY0.82%
OCF(TTM)1.69
OCFY2.24%
SpS27.11
BVpS17.5
TBVpS-4.48
PEG (NY)1.12
PEG (5Y)1.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.9% | ||
| ROE | 14.09% | ||
| ROCE | 9.55% | ||
| ROIC | 7.59% | ||
| ROICexc | 8.76% | ||
| ROICexgc | 20.16% | ||
| OM | 15.8% | ||
| PM (TTM) | 9.1% | ||
| GM | 54.02% | ||
| FCFM | 2.29% |
ROA(3y)4.55%
ROA(5y)4.81%
ROE(3y)10.72%
ROE(5y)11.21%
ROIC(3y)7.51%
ROIC(5y)8.04%
ROICexc(3y)8.78%
ROICexc(5y)9.36%
ROICexgc(3y)21.39%
ROICexgc(5y)20.4%
ROCE(3y)9.45%
ROCE(5y)10.11%
ROICexcg growth 3Y28.22%
ROICexcg growth 5Y5.14%
ROICexc growth 3Y32.37%
ROICexc growth 5Y-1.8%
OM growth 3Y24.43%
OM growth 5Y5.91%
PM growth 3Y-0.56%
PM growth 5Y9.58%
GM growth 3Y4.96%
GM growth 5Y3.61%
F-Score5
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.39 | ||
| Debt/FCF | 39.37 | ||
| Debt/EBITDA | 3.76 | ||
| Cap/Depr | 49.14% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 26.17% | ||
| Profit Quality | 25.13% | ||
| Current Ratio | 3.49 | ||
| Quick Ratio | 2.09 | ||
| Altman-Z | 2.73 |
F-Score5
WACC8.49%
ROIC/WACC0.89
Cap/Depr(3y)95.03%
Cap/Depr(5y)74.64%
Cap/Sales(3y)8.07%
Cap/Sales(5y)6.68%
Profit Quality(3y)138.01%
Profit Quality(5y)129.47%
High Growth Momentum
Growth
EPS 1Y (TTM)11.48%
EPS 3Y19.2%
EPS 5Y10.74%
EPS Q2Q%13.13%
EPS Next Y16.5%
EPS Next 2Y15.78%
EPS Next 3Y15.56%
EPS Next 5Y17.65%
Revenue 1Y (TTM)9.85%
Revenue growth 3Y14.57%
Revenue growth 5Y6.23%
Sales Q2Q%8.59%
Revenue Next Year7.65%
Revenue Next 2Y5.51%
Revenue Next 3Y6.63%
Revenue Next 5Y8.79%
EBIT growth 1Y16.93%
EBIT growth 3Y42.56%
EBIT growth 5Y12.51%
EBIT Next Year54.79%
EBIT Next 3Y20.82%
EBIT Next 5YN/A
FCF growth 1Y-73.25%
FCF growth 3Y17.16%
FCF growth 5Y23.43%
OCF growth 1Y-67.26%
OCF growth 3Y18.65%
OCF growth 5Y2.67%